Finance

Lists
Q2 2027 earnings • 5:00 AM tomorrow
See details
ZYDUSLIFE:NSE
Zydus Lifesciences Ltd
₹1,240.60
+0.01%
(+0.100) 1D
Nov 3, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for ZYDUSLIFE...
Open
₹1,244.70
High
₹1,245.90
Low
₹1,217.20
Mkt. cap
1.24T
Avg. vol.
1.59M
Volume
1.84M
Dividend
0.08%
Quarterly dividend
₹0.25
Ex-dividend date
Jul 24, 2026
P/E ratio
27.65
52-wk high
₹1,248.90
52-wk low
₹835.50
EPS
₹44.87
No. of employees
30K
Open
₹1,244.70
High
₹1,245.90
Low
₹1,217.20
Mkt. cap
1.24T
Avg. vol.
1.59M
Volume
1.84M
Dividend
0.08%
Quarterly dividend
₹0.25
Ex-dividend date
Jul 24, 2026
P/E ratio
27.65
52-wk high
₹1,248.90
52-wk low
₹835.50
EPS
₹44.87
No. of employees
30K
News stories
From web sources and news partners
Profile
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company, headquartered in Ahmedabad, India. Primarily engaged in the manufacturing of generic drugs, the company ranked 100th in the Fortune India 500 list in 2020. Wikipedia
About Zydus Lifesciences Ltd
CEO-
Employees30K
Founded1952
Headquarters-
SectorPharmaceutical industry
Websitezyduslife.com
Next call in 16:13:06
Tomorrow, 5:00 AM
Fiscal period
Q2 2027
- / ₹8.78
Revenue / Est. (INR)
- / 75.88B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
61.23B
68.64B
75.87B
80.17B
Cost of goods sold
16.90B
18.36B
22.07B
22.40B
Cost of revenue
16.90B
18.36B
22.07B
22.40B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.34B
11.40B
32.92B
13.68B
Operating expense
31.33B
37.36B
39.40B
44.59B
Total operating expenses
48.23B
55.72B
61.48B
66.99B
Operating income
13.00B
12.92B
14.39B
13.18B
Other non operating income
1.09B
1.11B
-3.70B
1.06B
EBT including unusual items
16.93B
14.11B
16.59B
13.44B
EBT excluding unusual items
17.27B
14.96B
20.88B
13.63B
Income tax expense
4.54B
3.88B
3.18B
3.54B
Effective tax rate
26.82%
27.52%
19.19%
26.35%
Other operating expenses
17.97B
22.36B
1.28B
25.36B
Net income
12.59B
10.42B
12.72B
9.40B
Net profit margin
20.55%
15.18%
16.77%
11.72%
Earnings per share
12.76
10.96
15.84
9.48
Interest and investment income
-
-
4.24B
-
Interest expense
-1.01B
-1.30B
-491.00M
-1.56B
Net interest expenses
-1.01B
-1.30B
3.75B
-1.56B
Depreciation and amortization charges
3.02B
3.60B
5.08B
5.55B
EBITDA
15.70B
15.10B
17.74B
16.53B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps